Research With Retinal Cells Derived From Stem Cells for Myopic Macular Degeneration

PHASE1/PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2013

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions
Myopic Macular Degeneration
Interventions
BIOLOGICAL

MA09-hRPE Cellular Therapy

A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Ocata Therapeutics

INDUSTRY

lead

University of California, Los Angeles

OTHER